The DOI matches its Crossref record; 264 of the 266 references it cites were found in a registry or an index; 149 of the 278 sources its claims cite were checked for support.
From serendipity to strategy: molecular glue degraders in cancer therapeutics
Open accessAbstract
Targeted protein degradation is an elegant therapeutic strategy that harnesses the cell's own degradation machinery to selectively eliminate target proteins. This approach marks a paradigm shift in drug discovery, moving beyond traditional occupancy-based inhibition toward target degradation, thereby silencing proteins that have historically resisted pharmacological intervention. Degrader molecules function by inducing proximity between target proteins and effectors, most commonly E3 ubiquitin ligases, triggering their ubiquitylation and proteasomal degradation. Molecular glue degraders - monovalent small molecules that promote these neo-interactions - have emerged as powerful tools in this space. Serendipity was once synonymous with molecular glue discovery, but increasing mechanistic understanding is now guiding their rational design. In this review, we trace their evolution from chance discovery, explore the biological mechanisms that underpin molecular glue activity, examine key examples that have advanced into the clinic, and discuss the challenges that remain in harnessing these compounds for broader therapeutic impact.
Overview
CoChat Summary
TL;DR
Molecular glue degraders are monovalent small molecules that induce or stabilize ternary complexes between target proteins and E3 ubiquitin ligases, driving selective proteasomal degradation of proteins previously considered undruggable. This review traces their evolution from serendipitous natural-product and IMiD discoveries toward rational design, highlighting clinical successes and remaining challenges in cancer therapeutics.
Key findings
- Molecular glue degraders can target proteins lacking defined pockets; the review states that >85% of proteins from disease-causing genes are considered “undruggable,” and that degraders act sub-stoichiometrically rather than through 1:1 occupancy.
- IMiDs thalidomide, lenalidomide, and pomalidomide degrade IKZF1/IKZF3 via CRBN; lenalidomide also degrades CK1α in 5q-MDS. For IKZF1 degradation, celMoD potency is listed as CFT7455 > mezigdomide > CC-99282 > iberdomide > avadomide > pomalidomide > lenalidomide > thalidomide.
- Additional glue mechanisms include SPLAMs such as indisulam/e7820 stabilizing RBM39–DCAF15 (ternary Kd 0.1 µM vs DCAF15–RBM39 ~5 µM and DCAF15–indisulam >20 µM), UM171 with InsP6 increasing HDAC1 affinity for CRL3-KBTBD4 by 25-fold, and BI-3802 inducing BCL6 polymerization and SIAH1-mediated degradation.
- Clinically, >70% of molecular glue degraders in use or trials target IKZF1/IKZF3; 18 PROTACs are in clinical trials, 13 of which use CRL4-CRBN. Iberdomide and mezigdomide are in Phase III, e7820 in Phase II, NVP-DKY709 in Phase I, MRT-2359 in Phase I/II, and KPG-121 in Phase II/III.
Methods
- Narrative review of published literature on molecular glue degraders, their mechanisms, discovery strategies, and clinical development in cancer.
- No primary experimental data, systematic search strategy, inclusion criteria, or meta-analysis are reported; the synthesis draws on cited preclinical studies, structural studies, and clinical trials.
- The review organizes evidence thematically: historical serendipitous discoveries, CRBN/IMiD biology, alternative E3 ligases and glue mechanisms, rational screening/design platforms, and clinical targets including IKZF1/3, IKZF2, GSPT1, RBM39, CK1α, cyclin K, and NEK7.
Limitations
- The paper states that clinical efficacy of molecular glues is still at an early stage and requires careful monitoring for glue-induced toxicities, including unintended disruption of an E3 ligase’s native substrates, especially with pan-tissue effectors such as CRBN.
- The paper notes resistance challenges: CRBN mutations occur in approximately 30% of relapsed/refractory myeloma patients versus <1% in newly diagnosed patients; sulfonamides have shown modest clinical responses, and e7820 showed a discrepancy between 50% RBM39 loss in a Phase II trial and 90% loss in preclinical models.
- Evident from the text: as a narrative review, it does not systematically appraise study quality or provide quantitative synthesis, and several clinical programs are described as ongoing or promising without mature outcome data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
117 Valid · 4 Not valid · 72 Not checked · 60 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“A comprehensive structural analysis of unbound cRBN and its iMiD-and substrate-bound counterpart revealed that cRBN harbors a high-degree of flexibility within its c-terminal substrate binding domain (Hartmann et al. 2015).”
§ molecular glue degraders in cancer therapeutics > CRBN's expanding potential as a master effector
What the sources say
- Supportedcites Hartmann et al. 2015 source
The Conclusions report an unexpected degree of structural flexibility in the thalidomide-binding domain, with three interconnected flexible regions that fold upon substrate binding. The Results and Discussion section on mouse cereblon says this flexibility is also relevant to animal cereblon. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the second breakthrough came in 2014 when a series of landmark studies revealed that thalidomide, and its more potent derivative lenalidomide, did not behave as inhibitors but in fact functioned as molecular glue degraders analogous to the auxin degrader tiR1 (chamberlain et al. 2014;Fischer et al. 2014;gandhi et al. 2014;Krönke et al. 2014;lu et al. 2014).”
§ molecular glue degraders in cancer therapeutics > Thalidomide's target -cereblon
What the sources say
- Not checked — no full text of the sourcecites Chamberlain et al. 2014 source
- Partly supportedcites Fischer et al. 2014 sourceExperimental — accuracy not yet measured
The paper’s Abstract and “Thalidomide is an agonist and antagonist” section describe IMiD-driven Ikaros/Aiolos degradation and explicitly compare the proposed mechanism with auxin-induced degradation by TIR1. But the claim’s contrast with inhibitors is too absolute: the paper also says IMiDs block recruitment of the endogenous substrate MEIS2. It describes lenalidomide as more effective than thalidomide at targeting Ikaros for degradation. (LLM, conf=0.88)
- Partly supportedcites Gandhi et al. 2014 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that lenalidomide promotes CRL4CRBN-mediated recruitment and degradation of Ikaros and Aiolos, rather than simply inhibiting the ligase. The paper studies lenalidomide and pomalidomide, not thalidomide as a degrader, and the cited passages do not establish an analogy to auxin–TIR1. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“By conjugating JQ1 to a thalidomide derivative, dBet1 successfully recruited cRBN to induce rapid and selective degradation of BRD2, BRD3 and BRD4.”
§ molecular glue degraders in cancer therapeutics > CRBN's expanding potential as a master effector
What the sources say
- Supportedcites Winter et al. 2015 source
The paper’s text (section labelled Abstract; page unavailable) describes dBET1 as a JQ1–phthalimide conjugate that promotes CRBN-dependent BET protein degradation. Its proteomic results report marked depletion of BRD2, BRD3 and BRD4 after two hours, with high specificity among 7,429 detected proteins; a separate time course shows rapid BRD4 loss. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A prime example that has reached the clinic is ARv-471, an estrogen receptor-targeting PROtAc, now in Phase iii trials for eR+ metastatic breast cancer (Nct05654623) (Hamilton et al. 2024).”
§ molecular glue degraders in cancer therapeutics > CRBN's expanding potential as a master effector
What the sources say
- Not matchedcites NCT05654623
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Hamilton et al. 2024 source
The Background section identifies vepdegestrant as ARV-471 and an estrogen receptor-targeting PROTAC degrader. The VERITAC-2 Study design section identifies NCT05654623 as a Phase III trial in adults with ER+/HER2- advanced breast cancer, and the Assignment to interventions section says enrollment was ongoing. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“their recruitment to cRl4 cRBN , upon lenalidomide treatment, led to their selective ubiquitylation and proteasomal degradation, ablating their role at promoters of their target genes (Krönke et al. 2014;lu et al. 2014).”
§ molecular glue degraders in cancer therapeutics > Thalidomide's target -cereblon
What the sources say
- Partly supportedcites Krönke et al. 2014 sourceExperimental — accuracy not yet measured
The paper’s Abstract reports that lenalidomide promotes IKZF1 and IKZF3 binding to CRBN-CRL4, followed by selective ubiquitination and degradation. It also reports that depletion of IKZF3 de-represses the IL2 promoter in T cells. It does not establish loss of both factors’ roles at promoters of their target genes generally. (LLM, conf=0.83)
- Not matchedcites Lu et al. 2014
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
152 more claims · 75 with their cited sources checked
Create a free account to see all 253 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 80
- Probably not a substantial claim. 25
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ molecular glue degraders in cancer therapeutics > Future perspectives: degraders as a pancancer modality
“molecular glues, direct degraders, ProtaCs and hyts all recruit e3 ligases and rely on proteasomal degradation (blue).”
§ molecular glue degraders in cancer therapeutics > Molecular glue degraders: taking inspiration from nature
“unlike ProtaCs and molecular glues, which mediate degradation through e3 ligase recruitment, hyts bypass this, relying instead on the cell's innate ability to clear unfolded or aberrantly exposed hydrophobic proteins.”
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…belongs to the ikaros family and plays an important role in immune evasion is a transcription factor that has been successfully targeted using a glue degrader approach. tumors evade immune detection by disrupting adaptive immunity, a key hallmark of tumor progression (Hanahan and weinberg 2011).”
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · cited 2×
“…across the human tissue proteome showed that cRBN exhibits low tissue specificity, with medium or high expression scores across 44 tissue types (uhlén et al. 2015). cRBN’s pan tissue expression highlights its capacity to target a diverse array of aberrant proteins in disease-specific contexts,…”
(2023) · doi:10.1126/science · Cited by 6,063
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“Many cancers overexpress PD-l1, triggering this checkpoint and evading immune detection (Keir et al. 2008; Francisco et al. 2010).”
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 1×
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014; Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018). in AMl, RBM39…”
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 2×
“A race ensued; their combined research revealed that these natural products remodeled their target proteins, a group of proteins named the immunophilins, recruiting novel interacting proteins to form entirely new ternary complexes (liu et al. 1991; Brown et al. 1994; Sabatini et al. 1994).”
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · cited 1×
“Monovalent and bivalent degraders have been extensively reviewed elsewhere (Farnaby et al. 2021; Kastl et al. 2021; Békés et al. 2022; Konstantinidou and Arkin 2024; lemaitre et al. 2024; Robinson et al. 2024; tan et al. 2024; Zhong et al. 2024). in this review, we focus on molecular glue…”
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 3×
“…while auxin was the first molecular glue degrader to be described, it was not the first recorded use of induced proximity as a tool for targeted protein degradation. the concept of targeted protein degradation was first introduced by crews, Deshaies and colleagues in 2001 (Sakamoto et al. 2001).”
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 1×
“…that thalidomide could be repurposed as an anti-cancer agent. clinical trials in multiple myeloma showed promising results where it was thought that its anti-inflammatory properties could disrupt the dependence of myeloma on inflammatory signaling (Singhal et al. 1999; Barlogie et al. 2001).”
Cited by
PhenoDEL as a Novel Screening Strategy Based on Intracellular Protein Degradation ActivityPreprint
Onda, Y., Ochi, Y., Araki, T., Kageoka, M., Takeda, S., Yamada, K. D., Ueda, T., Ohno, K., Tanaka, M., Sakai, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690606 · Cited by 3
PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
Periyasamy, S., Jarrett, T., Truong, J., & Skouta, R. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2636394 · Cited by 2
Xu, L., Wang, B., Li, W., Luo, X., Wang, L., & Zheng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1820785 · Cited by 1
“A molecular glue degrader is a small molecule that induces or stabilizes an interaction between an E3 ubiquitin ligase and a target protein, promoting target ubiquitination and proteasomal degradation (168).”
Al-Karmalawy, A. A., Attia, M. I., Yousef, T. A., Al-Qazzan, M. B., Al-Akeedi, M., Khatib, A. O. A., & Hawas, S. S. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70261 · Cited by 2
Xu, N., Shao, J., Jiang, L., Zhao, H., & Zheng, W. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189653 · Cited by 2
Metadata
- Authors
- Darling, S., Bajrami, I., & West, S. C.
- Affiliations
- The Francis Crick Institute (GB)
- Corresponding author
- Darling, Sarah
- West, Stephen C.
- Venue
- Critical Reviews in Biochemistry and Molecular Biology
- Publisher
- Informa UK Limited
- Published
- 2025-10
- Volume
- 60
- Issue
- 4-6
- Pages
- 200-230
- ISSN
- 0045-6411 (ISSN-L)
- 1040-9238
- 1549-7798
- OpenAlex
- W4414691781
- Cited by
- 9
- References
- 258
- Citations by year
- 2026: 9
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Critical Reviews in Biochemistry and Molecular Biology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Francis Crick Institute (cc2098)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- molecular glues, targeted protein degradation, E3 ubiquitin ligase, ubiquitination, proteasomal degradation, cancer therapeutics, small molecule drug discovery
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Ubiquitination, Drug Discovery, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From serendipity to strategy: molecular glue degraders in cancer therapeutics. https://app.cochat.ai/papers/10.1080/10409238.2025.2564068
- The paper
- Darling, S., Bajrami, I., & West, S. C. (2025). From serendipity to strategy: molecular glue degraders in cancer therapeutics. Critical Reviews in Biochemistry and Molecular Biology. https://doi.org/10.1080/10409238.2025.2564068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.